JAMA vs Clinical Infectious Diseases: Which Journal Should You Choose?

JAMA asks whether the paper matters across medicine. CID asks whether it changes infectious-disease practice.

That difference is what should drive the submission decision.

If the paper becomes more persuasive when you explain its consequences to hospitalists, emergency physicians, internists, policymakers, or health-system leaders, JAMA can be realistic. If the paper becomes most convincing when written for antimicrobial stewardship teams, transplant-ID clinicians, HIV specialists, or infection-control experts, CID is usually the cleaner home.

JAMA wins when the infectious-disease study behaves like a broad clinical paper.

That usually means:

• a result with consequences well beyond ID specialists
• a paper that changes care pathways or health-system decisions
• a major screening, prevention, or policy implication
• a study that broad clinicians can understand quickly without much specialty framing

JAMA's editorial guidance is very consistent on this point. Editors are screening first for broad clinical significance and only then for technical quality.

CID wins when the paper is built for infectious-disease clinicians.

That includes:

• antimicrobial stewardship studies with usable management implications
• treatment-outcome papers with clear bedside decisions
• diagnostic studies that change how ID teams evaluate infection
• immunocompromised-host and transplant infection work with direct clinical relevance
• outbreak, prevention, or pathogen-specific studies that remain fundamentally field-facing

CID's editorial guidance are particularly clear that papers need more than microbiology interest. They need practical clinical meaning.

The JAMA source set repeatedly emphasizes health-services research, comparative-effectiveness work, and clinically important questions that matter across broad physician audiences. That makes JAMA more plausible than many authors expect for the right ID papers, especially when the consequences are systemic rather than organism-specific.

CID submission's editorial guidance centers four areas: antimicrobial resistance and stewardship, immunocompromised-host infections, emerging infections, and treatment-outcome studies. That gives you a very concrete editorial map. If your paper can't tell a clinician what changes in one of those domains, the fit weakens quickly.

The official author-guidance path through Oxford emphasizes article types, cover-letter framing, line-numbered manuscripts, and a tightly organized submission package. The journal's editorial guidance adds two practical points authors often miss: word discipline and a direct statement of clinical significance in the cover letter.

If a paper only makes full sense after a lot of pathogen-specific or ID-specific framing, JAMA usually becomes much harder, even when the study is excellent. That isn't a quality judgment. It's a readership judgment.

• the paper changes clinical thinking beyond the ID field
• the finding has health-system, policy, or broad general-clinical implications
• the manuscript gets stronger when written for all of medicine
• the main significance survives even after you remove most specialty-specific framing

That's the narrower lane.

• the paper is strongest as clinician-facing infectious-disease research
• the readers who most need it are ID clinicians
• the study changes diagnosis, treatment, prevention, or stewardship
• the paper becomes less persuasive when generalized too far
• the practical consequence lives mainly inside the specialty

That's often the more realistic first move.

This is a very normal cascade.

If JAMA rejects the paper because it's too specialty-defined, CID can be a strong next move.

That works especially well when:

• the science is strong
• the main weakness was breadth, not rigor
• the study still changes infectious-disease decision-making
• the paper already reads naturally as a clinician-facing ID manuscript

It works less well when the study is mostly descriptive, too lab-heavy, or still thin on clinical consequence. JAMA rejection for breadth can still point to CID. JAMA rejection for limited practical value often won't.

If the paper only fully lands for ID specialists, the mismatch becomes visible early. A broad cover letter can't rescue that.

The CID source pages are blunt about this. A paper can be technically fine and still be a weak CID submission if it doesn't change diagnosis, treatment, prevention, or patient management in a meaningful way.

JAMA's editorial guidance is explicit that title, abstract, early results, and tables must make the clinical implication obvious fast. If the significance only appears after a long specialty buildup, the paper feels weaker at first screen.

fit and submission's editorial guidance both warn about studies that are basically microbiology or observational description with a small layer of clinical language added later. CID editors see that quickly.

These are often cleaner CID papers unless the study changes policy or care across medicine broadly.

If the main readers are infectious-disease clinicians and microbiology-linked care teams, CID usually makes more sense. If the diagnostic consequence is broad across hospital medicine, JAMA becomes more plausible.

These can go either way. If the paper reads like a global or systems-level clinical event, JAMA can be realistic. If the manuscript is still mainly a specialty clinical management story, CID is usually better.

This is a classic CID lane unless the paper carries unusually broad general-clinical consequences.

A strong JAMA first page tells a broad physician audience immediately why the finding matters. The question, design, and practical implication have to land quickly.

A strong CID first page does something slightly different. It shows infectious-disease clinicians what will change in diagnosis, treatment, prevention, or management. The practical utility has to be visible without hype.

That difference sounds simple, but it's often the most honest pre-submission test.

Ask which sentence fits the manuscript better:

• "this changes what physicians broadly should do or think" points toward JAMA
• "this changes what infectious-disease clinicians should do or think" points toward Clinical Infectious Diseases

That sentence catches a lot of bad journal targeting early.

It also helps separate topic prestige from manuscript shape. A paper about a major pathogen can still be a CID paper if the logic and readership remain specialist.

CID can be the better strategic choice because it puts the paper in front of the exact clinicians who will use it. That matters for:

• stewardship programs
• transplant and immunocompromised-host management
• HIV and chronic infection care
• diagnosis and treatment pathways
• pathogen-specific decision-making

In those situations, CID isn't a consolation prize. It's often the more accurate editorial match.

That match can produce stronger review, clearer interpretation, and a better long-term audience than an overstretched general-medical submission.

Send to JAMA first if:

1. the paper has visible importance beyond the ID field
2. the main consequence is broad clinical, policy, or systems-level change
3. the paper becomes stronger when written for a general-medical audience

Send to Clinical Infectious Diseases first if:

1. the paper is strongest as clinician-facing ID research
2. the real audience is still infectious-disease practice
3. the study changes diagnosis, treatment, prevention, or stewardship
4. broadening the framing would make the manuscript less precise